Synovial Sarcoma

  • Murray F. Brennan
  • Cristina R. Antonescu
  • Robert G. Maki
Chapter

Abstract

Synovial sarcomas present typically as a mass lesion usually on the extremities. Historically thought to be associated with peripheral joints, it is clear that there is no association of this sarcoma with synovium per se. Clinical presentation is that of younger age groups than other sarcomas, predominantly a disease of adolescent and young adulthood. As our data set includes patients over age 16, we underemphasize the presence in adolescents (Fig. 8.1). Site distribution for this adult cohort is shown in Fig. 8.2.

Keywords

Toxicity Tyrosine Sarcoma Doxorubicin Neutropenia 

References

  1. 1.
    Haldar M, Hancock JD, Coffin CM, et al. A conditional mouse model of synovial sarcoma: insights into a myogenic origin. Cancer Cell. 2007;11(4):375–88.PubMedCrossRefGoogle Scholar
  2. 2.
    van de Rijn M, Barr FG, Xiong QB, et al. Poorly differentiated synovial sarcoma: an analysis of clinical, pathologic, and molecular genetic features. Am J Surg Pathol. 1999;23(1):106–12.PubMedCrossRefGoogle Scholar
  3. 3.
    Turc-Carel C, Dal Cin P, Limon J, et al. Involvement of chromosome X in primary cytogenetic change in human neoplasia: nonrandom translocation in synovial sarcoma. Proc Natl Acad Sci USA. 1987;84(7):1981–5.PubMedCrossRefGoogle Scholar
  4. 4.
    Lasota J, Jasinski M, Debiec-Rychter M, et al. Detection of the SYT-SSX fusion transcripts in formaldehyde-fixed, paraffin-embedded tissue: a reverse transcription polymerase chain reaction amplification assay useful in the diagnosis of synovial sarcoma. Mod Pathol. 1998;11(7):626–33.PubMedGoogle Scholar
  5. 5.
    Skytting B, Nilsson G, Brodin B, et al. A novel fusion gene, SYT-SSX4, in synovial sarcoma. J Natl Cancer Inst. 1999;91(11):974–5.PubMedCrossRefGoogle Scholar
  6. 6.
    Coindre JM, Pelmus M, Hostein I, et al. Should molecular testing be required for diagnosing synovial sarcoma? A prospective study of 204 cases. Cancer. 2003;98(12):2700–7.PubMedCrossRefGoogle Scholar
  7. 7.
    Kawai A, Woodruff J, Healey JH, et al. SYT-SSX gene fusion as a determinant of morphology and prognosis in synovial sarcoma. N Engl J Med. 1998;338(3):153–60.PubMedCrossRefGoogle Scholar
  8. 8.
    Saito T, Nagai M, Ladanyi M. SYT-SSX1 and SYT-SSX2 interfere with repression of E-cadherin by snail and slug: a potential mechanism for aberrant mesenchymal to epithelial transition in human synovial sarcoma. Cancer Res. 2006;66(14):6919–27.PubMedCrossRefGoogle Scholar
  9. 9.
    Saito T, Oda Y, Kawaguchi K, et al. E-cadherin mutation and Snail overexpression as alternative mechanisms of E-cadherin inactivation in synovial sarcoma. Oncogene. 2004;23(53):8629–38.PubMedCrossRefGoogle Scholar
  10. 10.
    Saito T, Oda Y, Sugimachi K, et al. E-cadherin gene mutations frequently occur in synovial sarcoma as a determinant of histological features. Am J Pathol. 2001;159(6):2117–24.PubMedCrossRefGoogle Scholar
  11. 11.
    Pervaiz N, Colterjohn N, Farrokhyar F, et al. A systematic meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma. Cancer. 2008;113(3):573–81.PubMedCrossRefGoogle Scholar
  12. 12.
    Sarcoma Meta-Analysis Collaboration. Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: meta-analysis of individual data. Lancet. 1997;350(9092):1647–54.CrossRefGoogle Scholar
  13. 13.
    Woll PJ, van Glabbeke M, Hohenberger P, et al. Adjuvant chemotherapy (CT) with doxorubicin and ifosfamide in resected soft tissue sarcoma (STS): interim analysis of a randomised phase III trial. J Clin Oncol (Meet Abstr). 2007;25 Suppl 18:10008.Google Scholar
  14. 14.
    Eilber FC, Brennan MF, Eilber FR, et al. Chemotherapy is associated with improved survival in adult patients with primary extremity synovial sarcoma. Ann Surg. 2007;246(1):105–13.PubMedCrossRefGoogle Scholar
  15. 15.
    Shiu MH, Hilaris BS, Harrison LB, et al. Brachytherapy and function-saving resection of soft tissue sarcoma arising in the limb. Int J Radiat Oncol Biol Phys. 1991;21(6):1485–92.PubMedCrossRefGoogle Scholar
  16. 16.
    Nori D, Schupak K, Shiu MH, et al. Role of brachytherapy in recurrent extremity sarcoma in patients treated with prior surgery and irradiation. Int J Radiat Oncol Biol Phys. 1991;20(6):1229–33.PubMedCrossRefGoogle Scholar
  17. 17.
    Eggermont AM, de Wilt JH, ten Hagen TL. Current uses of isolated limb perfusion in the clinic and a model system for new strategies. Lancet Oncol. 2003;4(7):429–37.PubMedCrossRefGoogle Scholar
  18. 18.
    Eggermont AM, Schraffordt Koops H, Lienard D, et al. Isolated limb perfusion with high-dose tumor necrosis factor-alpha in combination with interferon-gamma and melphalan for nonresectable extremity soft tissue sarcomas: a multicenter trial. J Clin Oncol. 1996;14(10):2653–65.PubMedGoogle Scholar
  19. 19.
    Grunhagen DJ, de Wilt JH, Graveland WJ, et al. The palliative value of tumor necrosis factor alpha-based isolated limb perfusion in patients with metastatic sarcoma and melanoma. Cancer. 2006;106(1):156–62.PubMedCrossRefGoogle Scholar
  20. 20.
    Fayette J, Coquard IR, Alberti L, et al. ET-743: a novel agent with activity in soft tissue sarcomas. Oncologist. 2005;10(10):827–32.PubMedCrossRefGoogle Scholar
  21. 21.
    Schoffski P, Ray-Coquard IL, Cioffi A, et al. Activity of eribulin mesylate in patients with soft-tissue sarcoma: a phase 2 study in four independent histological subtypes. Lancet Oncol. 2011;12(11):1045–52.PubMedCrossRefGoogle Scholar
  22. 22.
    Sleijfer S, Ray-Coquard I, Papai Z, et al. Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043). J Clin Oncol. 2009;27(19):3126–32.PubMedCrossRefGoogle Scholar
  23. 23.
    Robbins PF, Morgan RA, Feldman SA, et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol. 2011;29(7):917–24.PubMedCrossRefGoogle Scholar
  24. 24.
    Lubieniecka JM, de Bruijn DR, Su L, et al. Histone deacetylase inhibitors reverse SS18-SSX-mediated polycomb silencing of the tumor suppressor early growth response 1 in synovial sarcoma. Cancer Res. 2008;68(11):4303–10.PubMedCrossRefGoogle Scholar
  25. 25.
    Nguyen A, Su L, Campbell B, et al. Synergism of heat shock protein 90 and histone deacetylase inhibitors in synovial sarcoma. Sarcoma. 2009;2009:794901.PubMedCrossRefGoogle Scholar
  26. 26.
    Su L, Sampaio AV, Jones KB, et al. Deconstruction of the SS18-SSX fusion oncoprotein complex: insights into disease etiology and therapeutics. Cancer Cell. 2012;21(3):333–47.PubMedCrossRefGoogle Scholar
  27. 27.
    Ladanyi M. Correlates of SYT-SSX fusion type in synovial sarcoma: getting more complex but also more interesting? J Clin Oncol. 2005;23(15):3638–9.PubMedCrossRefGoogle Scholar
  28. 28.
    Guillou L, Benhattar L, Bonichon F, et al. Histologic grade, but not SYT-SSX fusion type, is an important prognostic factor in patients with synovial sarcoma: a multicenter, retrospective analysis. J Clin Oncol. 2004;22(20):4040–50.PubMedCrossRefGoogle Scholar
  29. 29.
    Lewis JJ, Antonescu CR, Leung DH, et al. Synovial sarcoma: a multivariate analysis of prognostic factors in 112 patients with primary localized tumors of the extremity. J Clin Oncol. 2000;18(10):2087–94.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • Murray F. Brennan
    • 1
  • Cristina R. Antonescu
    • 2
  • Robert G. Maki
    • 3
  1. 1.International Center & Department of SurgeryMemorial Sloan-Kettering Cancer CenterNew YorkUSA
  2. 2.Department of PathologyMemorial Sloan-Kettering Cancer CenterNew YorkUSA
  3. 3.Departments of Medicine Pediatrics, and OrthopaedicsMount Sinai School of MedicineNew YorkUSA

Personalised recommendations